Link to this page
The Drug-Drug Interactions Ontology
Last uploaded:
February 11, 2016
| Id | http://purl.obolibrary.org/obo/CHEBI_71223
http://purl.obolibrary.org/obo/CHEBI_71223
|
|---|---|
| Preferred Name | pralatrexate |
| Synonyms |
pralatrexate
(2S)-2-((4-((1RS)-1-((2,4-Diaminopteridin-6-yl)methyl)but-3-ynyl)benzoyl)amino)pentanedioic acid
(2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}amino)pentanedioic acid
N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid
pralatrexatum
Folotyn
N-{4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}-L-glutamic acid
(2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]phenyl}formamido)pentanedioic acid
C23H23N7O5
HSDB 7786
10-Propargyl-10-deazaaminopterin
pralatrexato
See more
See less
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| prefLabel | pralatrexate
|
|---|---|
| label | pralatrexate
|
| DBSynonym | pdx
|
| ATCCode | L01BA05
|
| Definition | Pralatrexate is an antimetabolite for the treatment of relapsed or refractory peripheral T-cell lymphoma. It is more efficiently retained in cancer cells than methotrexate. FDA approved on September 24, 2009.
A pteridine that is the N-4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl derivative of L-glutamic acid. Used for treatment of Peripheral T-Cell Lymphoma, an aggressive form of non-Hodgkins lymphoma.
|
| has pharmacological target | |
| inhibits | |
| type | |
| has role | |
| InChIKey | InChIKey=OGSBUKJUDHAQEA-WMCAAGNKSA-N
|
| is metabolised by | |
| AHFScode | 10:00
|
| Synonym |
pralatrexate
(2S)-2-((4-((1RS)-1-((2,4-Diaminopteridin-6-yl)methyl)but-3-ynyl)benzoyl)amino)pentanedioic acid
(2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}amino)pentanedioic acid
N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid
pralatrexatum
Folotyn
N-{4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}-L-glutamic acid
(2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]phenyl}formamido)pentanedioic acid
C23H23N7O5
HSDB 7786
10-Propargyl-10-deazaaminopterin
pralatrexato
See more
See less
|
| xref |
CiteXplore:20702104
KEGG DRUG:D05589
ChEBI:71223
CiteXplore:20669794
Patent:US6323205
Drugs.com:http://www.drugs.com/cdi/pralatrexate.html
CiteXplore:22362328
CiteXplore:22534814
CiteXplore:21417858
CiteXplore:20739433
CiteXplore:21841501
RxList:http://www.rxlist.com/folotyn-drug.htm
CiteXplore:23040436
CiteXplore:23032692
CiteXplore:21726160
CiteXplore:22789917
CASRN:146464-95-1
CiteXplore:23008944
ChEMBL:775697
CiteXplore:22394596
CiteXplore:22076116
CiteXplore:21179031
CiteXplore:23115213
CiteXplore:22542448
Patent:WO2007023243
Wikipedia:Pralatrexate
CiteXplore:21591544
Patent:US6028071
Reaxys:6624234
CiteXplore:22343388
National Drug Code Directory:48818-001-01
CiteXplore:21939422
CiteXplore:21956523
CiteXplore:22457602
CiteXplore:22921318
Patent:US2005267117
Wikipedia:http://en.wikipedia.org/wiki/Pralatrexate
CiteXplore:20622807
Patent:US2011190305
CiteXplore:21245435
See more
See less
|
| CASRN | 146464-95-1
|
| prefixIRI | obo2:CHEBI_71223
|
| is transported by | |
| SMILES |
Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1
NC1=NC2=NC=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N=C2C(N)=N1
|
| may interact with |
See more
See less
|
| InChI | InChI=1S/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18(27-15)19(24)29-23(25)30-20)12-4-6-13(7-5-12)21(33)28-16(22(34)35)8-9-17(31)32/h1,4-7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,30)/t14?,16-/m0/s1
|
| DBBrand | folotyn
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |